Jules Gadiot

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.

Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.

Journal: Nature communications
Published: September 09, 2024

Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance.

Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance.

Journal: Science translational medicine
Published: January 24, 2019

Inducing and exploiting vulnerabilities for the treatment of liver cancer.

Inducing and exploiting vulnerabilities for the treatment of liver cancer.

Journal: Nature
Published: October 18, 2018

Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice.

Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice.

Journal: International journal of molecular sciences
Published: October 28, 2016

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

Journal: Oncoimmunology
Published: August 16, 2016

Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.

Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.

Journal: Cancer immunology, immunotherapy : CII
Published: August 21, 2015

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.

Journal: Cancer immunology, immunotherapy : CII
Published: November 20, 2014

Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity.

Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity.

Journal: OncoTargets and therapy
Published: December 19, 2013

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma.

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma.

Journal: Oncoimmunology
Published: August 31, 2012

Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts.

Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts.

Journal: Cancer immunology, immunotherapy : CII
Published: June 19, 2012

Targeting BRAFV600E in an inducible murine model of melanoma.

Targeting BRAFV600E in an inducible murine model of melanoma.

Journal: The American journal of pathology
Published: December 02, 2011

Expression of the embryological morphogen Nodal in stage III/IV melanoma.

Expression of the embryological morphogen Nodal in stage III/IV melanoma.

Journal: Melanoma research
Published: October 18, 2011
Showing 1-12 of 12

Last Updated: 09/26/2026